Literature DB >> 2164706

Evaluation of RIT 4237 bovine rotavirus vaccine in newborn infants: correlation of vaccine efficacy to season of birth in relation to rotavirus epidemic period.

T Ruuska1, T Vesikari, A Delem, F E André, G M Beards, T H Flewett.   

Abstract

A single oral dose of bovine rotavirus vaccine RIT 4237 or placebo was given to 2 groups of 5-day-old infants, born in October 1984 (n = 244) and June 1985 (n = 245), who remained in follow-up for 2.8 and 2.0 years, respectively. The vaccine had no effect on the total number of detectable episodes of rotavirus diarrhoea: there were 22 cases in the vaccinees and 24 in the placebo recipients in the October group and 18 and 16 respectively in the June group. However, vaccination decreased significantly the clinical severity of rotavirus diarrhoea, as assessed by a numerical score 0-20; this vaccine effect was much greater in the infants born in October. The mean severity scores for vaccine and placebo recipients were 4.55 and 10.75 respectively in the October group (p less than 0.0001, t-test) and 8.2 and 11.6 respectively in the June group (p = 0.010, t-test). Vaccine-induced clinical protection against rotavirus diarrhoea did not correlate well with serological response after vaccination, but showed good correlation to the presence of rotavirus antibodies before the rotavirus epidemic season. It is concluded that bovine rotavirus vaccine is more efficacious when given immediately before the rotavirus epidemic season: the vaccine effect may be amplified by exposure to wild rotaviruses during the season.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2164706     DOI: 10.3109/00365549009027047

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  11 in total

Review 1.  Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.

Authors:  Olufemi Samuel Folorunso; Olihile M Sebolai
Journal:  Vaccines (Basel)       Date:  2020-06-27

Review 2.  Performance of rotavirus vaccines in developed and developing countries.

Authors:  Victoria Jiang; Baoming Jiang; Jacqueline Tate; Umesh D Parashar; Manish M Patel
Journal:  Hum Vaccin       Date:  2010-07

Review 3.  Rotavirus vaccines: an overview.

Authors:  K Midthun; A Z Kapikian
Journal:  Clin Microbiol Rev       Date:  1996-07       Impact factor: 26.132

4.  Efficacy, immunogenicity, and safety of two doses of a tetravalent rotavirus vaccine RRV-TV in Ghana with the first dose administered during the neonatal period.

Authors:  George E Armah; Albert Z Kapikian; Timo Vesikari; Nigel Cunliffe; Robert M Jacobson; D Bruce Burlington; Leonard P Ruiz
Journal:  J Infect Dis       Date:  2013-04-18       Impact factor: 5.226

Review 5.  Rotaviruses: from pathogenesis to vaccination.

Authors:  Harry B Greenberg; Mary K Estes
Journal:  Gastroenterology       Date:  2009-05-07       Impact factor: 22.682

6.  Identification of VP7 epitopes associated with protection against human rotavirus illness or shedding in volunteers.

Authors:  K Y Green; A Z Kapikian
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

7.  The performance of licensed rotavirus vaccines and the development of a new generation of rotavirus vaccines: a review.

Authors:  Yuxiao Wang; Jingxin Li; Pei Liu; Fengcai Zhu
Journal:  Hum Vaccin Immunother       Date:  2020-09-23       Impact factor: 3.452

8.  Rotavirus infection: a perspective on epidemiology, genomic diversity and vaccine strategies.

Authors:  Anupam Mukherjee; Mamta Chawla-Sarkar
Journal:  Indian J Virol       Date:  2011-06-14

Review 9.  Rotavirus.

Authors:  U D Parashar; J S Bresee; J R Gentsch; R I Glass
Journal:  Emerg Infect Dis       Date:  1998 Oct-Dec       Impact factor: 6.883

10.  Incidence of rotavirus gastroenteritis by age in African, Asian and European children: Relevance for timing of rotavirus vaccination.

Authors:  A Duncan Steele; Shabir A Madhi; Nigel A Cunliffe; Timo Vesikari; Kong Boo Phua; Fong Seng Lim; E Anthony S Nelson; Yu-Lung Lau; Li-Min Huang; Naveen Karkada; Serge Debrus; Htay Htay Han; Bernd Benninghoff
Journal:  Hum Vaccin Immunother       Date:  2016-06-03       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.